As of November 8, 2026, 7 holders' latest Schedule 13D or 13G filings report owning 5% or more of Indaptus Therapeutics, Inc. The largest reported stake is Lazar David E.'s, at 47.93%. 15 filings are on record since December 30, 2025 (Schedule 13D/A, March 24, 2026).
Sell to companies like Indaptus Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Yao Yun · Sole voting: 41,991,000 · Shared voting: 0 · Sole dispositive: 41,991,000 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-10-22
- · Reporting person: Sino Lion Ventures Ltd · Sole voting: 0 · Shared voting: 38,895,000 · Sole dispositive: 0 · Shared dispositive: 38,895,000 · SCHEDULE 13D/A, 2026-10-22
- · Reporting person: Dai Junyi · Sole voting: 11,250,000 · Shared voting: 0 · Sole dispositive: 11,250,000 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-10-22
- · Reporting person: Yang Ting · Sole voting: 9,948,173 · Shared voting: 0 · Sole dispositive: 9,948,173 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-10-21
- · Holder: Yao Yun · Percent: 31.51% · SCHEDULE 13D/A
Indaptus Therapeutics, Inc. has 15 Schedule 13D or 13G filings on record since 2025-12-30. 7 holders' latest filing reports 5% or more of common stock, par value $0.01 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 47.93% | 2,064,000 | SCHEDULE 13D/A, 2026-03-24 | 2026-03-23 | |
| 27.34% | 41,991,000 | SCHEDULE 13D/A, 2026-10-22 | 2026-10-16 | |
| Sino Lion Ventures Ltd | 25.33% | 38,895,000 | SCHEDULE 13D/A, 2026-10-22 | 2026-10-16 |
| 12.7% | 273,103 | SCHEDULE 13D/A, 2025-12-30 | 2025-12-22 | |
| 7.33% | 11,250,000 | SCHEDULE 13D/A, 2026-10-22 | 2026-10-16 | |
| 6.48% | 9,948,173 | SCHEDULE 13D/A, 2026-10-21 | 2026-10-16 | |
| 5.4% | 115,552 | SCHEDULE 13D/A, 2025-12-30 | 2025-12-22 | |
| YA II PN, Ltd. | 0% | 0 | SCHEDULE 13G/A, 2026-04-06 | 2025-12-31 |
Holding shares or following this stake? See who's behind Indaptus Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Indaptus Therapeutics, Inc. and the records around it.
The people at Indaptus Therapeutics, Inc.
- Hila Karah is also named on 9 other Form D filings: DarioHealth Corp. (Oct 2025)
Indaptus Therapeutics, Inc. elsewhere on the record
- Leadership changes Sep 2026
- Form D filing Jun 2025
- Who owns it
Companies that share a holder
- Lazar David E. also filed stake reports on 8 other companies: HIGHWAY HOLDINGS LTD (Nov 2026), Aterian, Inc. (Sep 2026), MAINZ BIOMED N.V. (Aug 2026)
- YA II PN, Ltd. also filed stake reports on 13 other companies: Ives Ultra AI Opportunities Inc. (Oct 2026), Beneficient (Oct 2026), Optimi Health Corp. (Oct 2026)
Watch Indaptus Therapeutics, Inc.
Get an email when Indaptus Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Indaptus Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Indaptus Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Indaptus Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
23 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Yao Yun | 41,991,000 | 0 | 41,991,000 | 0 | SCHEDULE 13D/A, 2026-10-22 |
| Sino Lion Ventures Ltd | 0 | 38,895,000 | 0 | 38,895,000 | SCHEDULE 13D/A, 2026-10-22 |
| Chenhao Xu | 0 | 38,895,000 | 0 | 38,895,000 | SCHEDULE 13D/A, 2026-10-22 |
| Dai Junyi | 11,250,000 | 0 | 11,250,000 | 0 | SCHEDULE 13D/A, 2026-10-22 |
| Yang Ting | 9,948,173 | 0 | 9,948,173 | 0 | SCHEDULE 13D/A, 2026-10-21 |
The latest filing identifies Indaptus Therapeutics, Inc. by CUSIP 45339J105 and gives its principal executive office as c/o Indaptus Therapeutics, Inc., 3 Columbus Circle, 15th Floor, New York, NY 10019 (SCHEDULE 13D/A, 2026-10-22).
Source of funds (Item 3)
The Series AAA Preferred Stock was purchased by Ms. Yao pursuant to the Securities Purchase Agreement, dated as of March 19, 2026 (the "Purchase Agreement") between David Lazar, Yun Yao, Sino Lion Ventures Limited, Junyi Dai, Ting Yang, and Lina Deng. The Purchase Agreement closed on March 23, 2026. Ms. Yao used personal funds in the aggregate amount of $4,317,206.43 to fund her purchase.Yao Yun, SCHEDULE 13D/A, 2026-10-22
The Series AAA Preferred Stock was purchased by the Reporting Persons pursuant to the Securities Purchase Agreement, dated as of March 19, 2026 (the "Purchase Agreement") between David Lazar, Yun Yao, Sino Lion Ventures Limited, Junyi Dai, Ting Yang, and Lina Deng. The Purchase Agreement closed on March 23, 2026. Sino Lion Ventures Limited used working capital in the aggregate amount of $3,998,898.44 to fund its purchase.Sino Lion Ventures Ltd, SCHEDULE 13D/A, 2026-10-22
The Series AAA Preferred Stock was purchased by Mr. Dai pursuant to the Securities Purchase Agreement, dated as of March 19, 2026 (the "Purchase Agreement") between David Lazar, Yun Yao, Sino Lion Ventures Limited, Junyi Dai, Ting Yang, and Lina Deng. The Purchase Agreement closed on March 23, 2026. Mr. Dai used personal funds in the aggregate amount of $1,156,642.43 to fund his purchase.Dai Junyi, SCHEDULE 13D/A, 2026-10-22
The Series AAA Preferred Stock was purchased by Ting Yang pursuant to the Securities Purchase Agreement, dated as of March 19, 2026 (the "Purchase Agreement") between David Lazar, Yun Yao, Sino Lion Ventures Limited, Junyi Dai, Ting Yang, and Lina Deng. The Purchase Agreement closed on March 23, 2026. Ting Yang used his personal funds in the aggregate amount of $1,156,642.43 to fund his purchase.Yang Ting, SCHEDULE 13D/A, 2026-10-21
Purpose of Transaction (Item 4)
Lazar David E.
Item 4 is hereby amended to add the following: Following the completion of the transactions set forth in the March 2026 SPA (as defined below), the Reporting Person has resigned as co-Chief Executive Officer of the Issuer. The Reporting Person will remain a member of the Issuer's Board of Directors.Item 4 of the SCHEDULE 13D/A filed 2026-03-24
Yao Yun
The information set forth in Item 4 in the Initial Schedule 13D is incorporated herein by reference. This Amendment No. 3 is being filed to report a decrease of more than 1% in the percentage of the outstanding Common Stock beneficially owned by the Reporting Person, resulting solely from the issuance of 20,338,974 shares of Common Stock in connection with the closing of the Issuer's private placement on October 16, 2026, as reported in the Issuer's Current Report on Form 8-K filed with the SEC on October 20, 2026. The Reporting Person did not acquire or dispose of any shares of Common Stock in connection therewith.Item 4 of the SCHEDULE 13D/A filed 2026-10-22
Yang Ting
The information set forth in Item 4 of the Original Schedule 13D is incorporated herein by reference. This Amendment No. 3 is being filed to report a decrease in the percentage of the outstanding Common Stock beneficially owned by the Reporting Person resulting from (i) the Reporting Person's disposition of an aggregate of 1,301,827 shares of Common Stock and (ii) the issuance of 20,338,974 shares of Common Stock in connection with the closing of the Issuer's private placement on October 16, 2026, as reported in the Issuer's Current Report on Form 8-K filed with the SEC on October 20, 2026. Following these changes, the Reporting Person beneficially owns 9,948,173 shares of Common Stock, representing approximately 6.48% of the outstanding Common Stock.Item 4 of the SCHEDULE 13D/A filed 2026-10-21
Dai Junyi
The information set forth in Item 4 in the Initial Schedule 13D is incorporated herein by reference. This Amendment No. 3 is being filed to report a decrease of more than 1% in the percentage of the outstanding Common Stock beneficially owned by the Reporting Person, resulting solely from the issuance of 20,338,974 shares of Common Stock in connection with the closing of the Issuer's private placement on October 16, 2026, as reported in the Issuer's Current Report on Form 8-K filed with the SEC on October 20, 2026. The Reporting Person did not acquire or dispose of any shares of Common Stock in connection therewith.Item 4 of the SCHEDULE 13D/A filed 2026-10-22
Sino Lion Ventures Ltd
The information set forth in Item 4 in the Initial Schedule 13D is incorporated herein by reference. This Amendment No. 3 is being filed to report a decrease of more than 1% in the percentage of the outstanding Common Stock beneficially owned by the Reporting Persons, resulting solely from the issuance of 20,338,974 shares of Common Stock in connection with the closing of the Issuer's private placement on October 16, 2026, as reported in the Issuer's Current Report on Form 8-K filed with the SEC on October 20, 2026. The Reporting Persons did not acquire or dispose of any shares of Common Stock in connection therewith.Item 4 of the SCHEDULE 13D/A filed 2026-10-22
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-12-30 | Newman Michael James | 5.4% | SCHEDULE 13D/A |
| 2025-12-30 | Jeffery A. Meckler | 12.7% | SCHEDULE 13D/A |
| 2026-03-02 | Lazar David E. | 98% | SCHEDULE 13D |
| 2026-03-24 | Lazar David E. | 47.93% | SCHEDULE 13D/A |
| 2026-03-30 | Yao Yun | 37.8% | SCHEDULE 13D |
| 2026-04-06 | YA II PN, Ltd. | 0% | SCHEDULE 13G/A |
| 2026-04-29 | Yao Yun | 37.1% | SCHEDULE 13D/A |
| 2026-06-26 | Yao Yun | 31.51% | SCHEDULE 13D/A |
| 2026-06-26 | Yang Ting | 8.44% | SCHEDULE 13D/A |
| 2026-06-26 | Dai Junyi | 8.44% | SCHEDULE 13D/A |
| 2026-06-26 | Sino Lion Ventures Ltd | 29.19% | SCHEDULE 13D/A |
| 2026-10-21 | Yang Ting | 6.48% | SCHEDULE 13D/A |
| 2026-10-22 | Yao Yun | 27.34% | SCHEDULE 13D/A |
| 2026-10-22 | Dai Junyi | 7.33% | SCHEDULE 13D/A |
| 2026-10-22 | Sino Lion Ventures Ltd | 25.33% | SCHEDULE 13D/A |
Questions about who owns Indaptus Therapeutics, Inc.
Who owns Indaptus Therapeutics, Inc.?
On this page, 7 holders' latest ownership filings report 5% or more of Indaptus Therapeutics, Inc.: Lazar David E. (47.93%, Schedule 13D/A, filed 2026-03-24), Yao Yun (27.34%, Schedule 13D/A, filed 2026-10-22), Sino Lion Ventures Ltd (25.33%, Schedule 13D/A, filed 2026-10-22), Jeffery A. Meckler (12.7%, Schedule 13D/A, filed 2025-12-30) and Dai Junyi (7.33%, Schedule 13D/A, filed 2026-10-22); 2 more are listed above.
Who are the largest shareholders of Indaptus Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Indaptus Therapeutics, Inc. on this page are Lazar David E. (47.93%), Yao Yun (27.34%) and Sino Lion Ventures Ltd (25.33%).
When did Lazar David E. buy into Indaptus Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Lazar David E. on this page is the Schedule 13D, filed 2026-03-02, reporting 98%; its latest, Schedule 13D/A filed 2026-03-24, reports 47.93%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 15 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Indaptus Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 4, 2026 | Leadership change: Tim Ruan departs | — | Leadership changes | Source |
| June 5, 2026 | Leadership change: Walt A. Linscott appointed, Chief Operating Officer | — | Leadership changes | Source |
| April 24, 2026 | Leadership change: Tim Ruan appointed, Director, and 2 more | — | Leadership changes | Source |
| April 23, 2026 | Leadership change: Tim Ruan appointed, Director, and 2 more | — | Leadership changes | Source |
| April 3, 2026 | Leadership change: Qinglai Lu appointed, Director | — | Leadership changes | Source |
| June 20, 2025 | Form D, private offering | $2.31M sold | Form D page | Source |
| January 22, 2025 | Form D, private offering | $2.25M sold | Form D page | Source |
| December 6, 2024 | Form D, private offering | $227K sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Indaptus Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.